Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382702 · ClinicalTrials.gov registry record · NA
Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
A NA study of Feeding and Eating Disorders, sponsored by Ohio University.
- Recruiting
- Registry status
- NA
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT05382702: Recruiting NA study of Feeding and Eating Disorders, sponsored by Ohio University.
NCT05382702 is a NA study of Feeding and Eating Disorders that is actively recruiting participants, run by Ohio University. The registered enrollment target is 152 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382702, a NA study of Feeding and Eating Disorders, is actively recruiting participants, sponsored by Ohio University.
- RECRUITING
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study tests fear, gut peptide response, and perceptions of fullness as causes of gastrointestinal distress and eating disorder maintenance.
Primary Outcome
Area under the curve with respect to increase (AUCi) from the 10 minutes period prior to the meal until immediately after the meal will be used to characterize changes in Visual Analogue Scale ratings of momentary fear ranging from "Not at All (0)" to "Extreme (100)." AUCi was calculated as: (((Fear at -10 minutes)+ (Fear at 0 minutes))\*10/2) + (((Fear at 0 Minutes)+(Fear at +10 minutes))\*10/2) - (Fear at -10 minutes)\*20. A more positive score indicates greater increases in fear over the pre
Conditions Studied
Interventions
- OTHER Test meal description changed
Study Locations (1)
Ohio
- Ohio University - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT05382702 shows while recruiting
NCT05382702 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Feeding and Eating Disorders appearing as the primary indexed condition, and to 1 intervention - of which Test meal description changed is the first listed.
NCT05382702 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05382702 about?
NCT05382702 is a clinical study titled "Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders". The proposed study tests fear, gut peptide response, and perceptions of fullness as causes of gastrointestinal distress and eating disorder maintenance.
What is the current status of trial NCT05382702?
This trial is currently recruiting. It is a NA study. The enrollment target is 152 participants. The study started on 2022-04-22. Estimated completion is 2025-12-31.
What conditions does trial NCT05382702 study?
This clinical trial studies the following conditions: Feeding and Eating Disorders.
What interventions are being tested in trial NCT05382702?
The interventions under investigation include: Test meal description changed (OTHER).
Who is sponsoring clinical trial NCT05382702?
This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05382702 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Feeding and Eating Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05382702's enrollment target sits among peer trials
152 658th of 2000 higher than 1,340 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI